{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:54:07Z","timestamp":1788454447380,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["106-2314-B-002-226-MY3"],"award-info":[{"award-number":["106-2314-B-002-226-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["108-2628-B-002-015"],"award-info":[{"award-number":["108-2628-B-002-015"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["109-2314-B-002-213"],"award-info":[{"award-number":["109-2314-B-002-213"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 2022, two novel classification systems for myelodysplastic syndromes\/neoplasms (MDS) have been proposed: the International Consensus Classification (ICC) and the 2022 World Health Organization (WHO-2022) classification. These two contemporary systems exhibit numerous shared features but also diverge significantly in terminology and the definition of new entities. Thus, we retrospectively validated the ICC and WHO-2022 classification and found that both systems promoted efficient segregation of this heterogeneous disease. After examining the distinction between the two systems, we showed that a peripheral blood blast percentage \u2265\u20095% indicates adverse survival. Identifying MDS\/acute myeloid leukemia with MDS-related gene mutations or cytogenetic abnormalities helps differentiate survival outcomes. In MDS, not otherwise specified patients, those diagnosed with hypoplastic MDS and single lineage dysplasia displayed a trend of superior survival compared to other low-risk MDS patients. Furthermore, the impact of bone marrow fibrosis on survival was less pronounced within the ICC framework. Allogeneic transplantation appears to improve outcomes for patients diagnosed with MDS with excess blasts in the ICC. Therefore, we proposed an integrated system that may lead to the accurate diagnosis and advancement of future research for MDS. Prospective studies are warranted to validate this refined classification.<\/jats:p>","DOI":"10.1038\/s41408-024-01031-9","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T03:02:21Z","timestamp":1712631741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes\/neoplasms"],"prefix":"10.1038","volume":"14","author":[{"given":"Wan-Hsuan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Cheng-Hong","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-2472","authenticated-orcid":false,"given":"Feng-Ming","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Yen","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Hsuan","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-9000","authenticated-orcid":false,"given":"Yuan-Yeh","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Chi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chih","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Tsu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Tsung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Kai","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jih-Luh","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsun-I","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Kuang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-5593","authenticated-orcid":false,"given":"Hwei-Fang","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-4845","authenticated-orcid":false,"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2967-698X","authenticated-orcid":false,"given":"Wen-Chien","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"1031_CR1","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1056\/NEJMra0902908","volume":"361","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872\u201385.","journal-title":"N Engl J Med"},{"key":"1031_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2022.14578","volume":"328","author":"MA Sekeres","year":"2022","unstructured":"Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. Jama. 2022;328:872\u201380.","journal-title":"Jama"},{"key":"1031_CR3","unstructured":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopietic and Lymphoid Tissues (ed 3rd). Lyon: IARC Press; (2001)."},{"key":"1031_CR4","unstructured":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. In: Swerdlow SHCE, Harris NL, et al., editor: Lyon: IARC; (2008)."},{"key":"1031_CR5","unstructured":"Swerdlow SHCE, Harris NL, et al. eds. WHO Classification fo Tumours of Haematopoietic and Lymphoid Tissues.: Lyon: IARC; (2017)."},{"key":"1031_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1031_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/bjh.16212","volume":"188","author":"TP Spaulding","year":"2020","unstructured":"Spaulding TP, Stockton SS, Savona MR. The evolving role of next generation sequencing in myelodysplastic syndromes. Br J Haematol. 2020;188:224\u201339.","journal-title":"Br J Haematol"},{"key":"1031_CR8","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3390\/diagnostics12071581","volume":"12","author":"FPT Tria","year":"2022","unstructured":"Tria FPT, Ang DC, Fan G. Myelodysplastic syndrome: diagnosis and screening. Diagnostics (Basel). 2022;12:1581.","journal-title":"Diagnostics (Basel)"},{"key":"1031_CR9","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1031_CR10","unstructured":"WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet; beta version ahead of print]. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2024 Jan 23th]. (WHO classification of tumours series, 5th ed.; vol. 11). Available from: https:\/\/tumourclassification.iarc.who.int\/chapters\/63."},{"key":"1031_CR11","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Ossa JEA, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evidence"},{"key":"1031_CR12","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"1031_CR13","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1038\/s41375-019-0479-8","volume":"33","author":"D Singhal","year":"2019","unstructured":"Singhal D, Wee LYA, Kutyna MM, Chhetri R, Geoghegan J, Schreiber AW, et al. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia. 2019;33:2842\u201353.","journal-title":"Leukemia"},{"key":"1031_CR14","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.3324\/haematol.2019.219352","volume":"105","author":"T Kuzmanovic","year":"2020","unstructured":"Kuzmanovic T, Patel BJ, Sanikommu SR, Nagata Y, Awada H, Kerr CM, et al. Genomics of therapy-related myeloid neoplasms. Haematologica. 2020;105:e98\u2013e101.","journal-title":"Haematologica"},{"key":"1031_CR15","unstructured":"International Standing Committee on Human Cytogenomic Nomenclature M-JJHRJMSSKG. ISCN 2020 an International System for Human Cytogenomic Nomenclature (2020): recommendations of the International Standing Committee on Human Cytogenomic Nomenclature including revised sequence-based cytogenomic nomenclature developed in collaboration with the Human Genome Variation Society (HGVS) Sequence Variant Description Working Group (2020)."},{"key":"1031_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00894-8","volume":"13","author":"WH Lee","year":"2023","unstructured":"Lee WH, Tsai MT, Tsai XC-H, Tien FM, Lo MY, Tseng MH, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification. Blood Cancer J. 2023;13:120.","journal-title":"Blood Cancer J"},{"key":"1031_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","volume":"127","author":"D Grimwade","year":"2016","unstructured":"Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127:29\u201341.","journal-title":"Blood"},{"key":"1031_CR18","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/ajh.26734","volume":"97","author":"WH Lee","year":"2022","unstructured":"Lee WH, Lin CC, Tsai XC-H, Tseng MH, Kuo YY, Liu MC, et al. Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients. Am J Hematol. 2022;97:1589\u201398.","journal-title":"Am J Hematol"},{"key":"1031_CR19","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/bloodadvances.2020003738","volume":"5","author":"XC-H Tsai","year":"2021","unstructured":"Tsai XC-H, Tang JL, Tien FM, Kuo YY, Wu DC, Lin CC, et al. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Adv. 2021;5:2456\u201366.","journal-title":"Blood Adv"},{"key":"1031_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/sj.leu.2402352","volume":"16","author":"HS Shiah","year":"2002","unstructured":"Shiah HS, Kuo YY, Tang JL, Huang SY, Yao M, Tsay W, et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia. 2002;16:196\u2013202.","journal-title":"Leukemia"},{"key":"1031_CR21","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1182\/bloodadvances.2021004435","volume":"6","author":"R Devillier","year":"2022","unstructured":"Devillier R, Forcade E, Garnier A, Guenounou S, Thepot S, Guillerm G, et al. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Adv. 2022;6:1804\u201312.","journal-title":"Blood Adv"},{"key":"1031_CR22","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","volume":"33","author":"D Haase","year":"2019","unstructured":"Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019;33:1747\u201358.","journal-title":"Leukemia"},{"key":"1031_CR23","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"1031_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ajh.26812","volume":"98","author":"B Falini","year":"2023","unstructured":"Falini B, Martelli MP. Comparison of the international consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia. Am J Hematol. 2023;98:481\u201392.","journal-title":"Am J Hematol"},{"key":"1031_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/bjh.18628","volume":"201","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wu J, Xu Z, Qin T, Qu S, Pan L, et al. Impact of the international consensus classification of myelodysplastic syndromes. Br J Haematol. 2023;201:443\u20138.","journal-title":"Br J Haematol"},{"key":"1031_CR26","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/ajh.26799","volume":"98","author":"WH Lee","year":"2023","unstructured":"Lee WH, Lin CC, Tsai XC-H, Tien FM, Lo MY, Ni SC, et al. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome\/acute myeloid leukemia based on the 2022 international consensus classification. Am J Hematol. 2023;98:398\u2013407.","journal-title":"Am J Hematol"},{"key":"1031_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/cancers13010132","volume":"13","author":"B Fattizzo","year":"2021","unstructured":"Fattizzo B, Serpenti F, Barcellini W, Caprioli C. Hypoplastic myelodysplastic syndromes: just an overlap syndrome? Cancers (Basel). 2021;13:132.","journal-title":"Cancers (Basel)"},{"key":"1031_CR28","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.3324\/haematol.2015.130112","volume":"100","author":"A Nazha","year":"2015","unstructured":"Nazha A, Seastone D, Radivoyevitch T, Przychodzen B, Carraway HE, Patel BJ, et al. Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. Haematologica. 2015;100:e434\u20137.","journal-title":"Haematologica"},{"key":"1031_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.leukres.2007.08.006","volume":"32","author":"G Yue","year":"2008","unstructured":"Yue G, Hao S, Fadare O, Baker S, Pozdnyakova O, Galili N, et al. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res. 2008;32:553\u20138.","journal-title":"Leuk Res"},{"key":"1031_CR30","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/bjh.12955","volume":"166","author":"D Hasegawa","year":"2014","unstructured":"Hasegawa D, Chen X, Hirabayashi S, Ishida Y, Watanabe S, Zaike Y, et al. Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification. Br J Haematol. 2014;166:758\u201366.","journal-title":"Br J Haematol"},{"key":"1031_CR31","doi-asserted-by":"publisher","first-page":"63177","DOI":"10.18632\/oncotarget.11050","volume":"7","author":"CY Yao","year":"2016","unstructured":"Yao CY, Hou HA, Lin TY, Lin CC, Chou WC, Tseng MH, et al. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). Oncotarget. 2016;7:63177\u201388.","journal-title":"Oncotarget"},{"key":"1031_CR32","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.leukres.2013.01.019","volume":"37","author":"MR Lopes","year":"2013","unstructured":"Lopes MR, Traina F, Campos Pde M, Pereira JK, Machado-Neto JA, Machado Hda C, et al. IL10 inversely correlates with the percentage of CD8+ cells in MDS patients. Leuk Res. 2013;37:541\u20136.","journal-title":"Leuk Res"},{"key":"1031_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","volume":"29","author":"JR Passweg","year":"2011","unstructured":"Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33\/99. J Clin Oncol. 2011;29:303\u20139.","journal-title":"J Clin Oncol"},{"key":"1031_CR34","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ajh.24905","volume":"92","author":"T Kobayashi","year":"2017","unstructured":"Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, et al. A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). Am J Hematol. 2017;92:1324\u201332.","journal-title":"Am J Hematol"},{"key":"1031_CR35","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1038\/s41375-019-0457-1","volume":"33","author":"E Bono","year":"2019","unstructured":"Bono E, McLornan D, Travaglino E, Gandhi S, Gall\u00ec A, Khan AA, et al. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia. 2019;33:2495\u2013505.","journal-title":"Leukemia"},{"key":"1031_CR36","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/s41375-022-01592-3","volume":"36","author":"G Calabretto","year":"2022","unstructured":"Calabretto G, Attardi E, Teramo A, Trimarco V, Carraro S, Mossuto S, et al. Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. Leukemia. 2022;36:1947\u201350.","journal-title":"Leukemia"},{"key":"1031_CR37","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.clml.2020.01.003","volume":"20","author":"M Melody","year":"2020","unstructured":"Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, Sallman D, et al. Decoding bone marrow fibrosis in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2020;20:324\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1031_CR38","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/modpathol.2013.187","volume":"27","author":"B Fu","year":"2014","unstructured":"Fu B, Jaso JM, Sargent RL, Goswami M, Verstovsek S, Medeiros LJ, et al. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol. 2014;27:681\u20139.","journal-title":"Mod Pathol"},{"key":"1031_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1385\/MO:21:4:325","volume":"21","author":"D Marisavljevi\u0107","year":"2004","unstructured":"Marisavljevi\u0107 D, Rolovi\u0107 Z, Cemeriki\u0107 V, Boskovi\u0107 D, Colovi\u0107 M. Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance. Med Oncol. 2004;21:325\u201331.","journal-title":"Med Oncol"},{"key":"1031_CR40","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.2147\/CMAR.S258875","volume":"12","author":"N Wang","year":"2020","unstructured":"Wang N, Xu H, Li Q, Fang X, Liu J, Sui X, et al. Patients of myelodysplastic syndrome with mild\/moderate myelofibrosis and a monosomal karyotype are independently associated with an adverse prognosis: long-term follow-up data. Cancer Manag Res. 2020;12:5881\u201391.","journal-title":"Cancer Manag Res"},{"key":"1031_CR41","doi-asserted-by":"publisher","first-page":"30492","DOI":"10.18632\/oncotarget.9026","volume":"7","author":"F Ramos","year":"2016","unstructured":"Ramos F, Robledo C, Izquierdo-Garc\u00eda FM, Su\u00e1rez-Vilela D, Benito R, Fuertes M, et al. Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis. Oncotarget. 2016;7:30492\u2013503.","journal-title":"Oncotarget"},{"key":"1031_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3324\/haematol.2010.039875","volume":"96","author":"P Matteo Giovanni Della","year":"2011","unstructured":"Matteo Giovanni Della P, Luca M. Myelodysplastic syndromes with bone marrow fibrosis. Haematologica. 2011;96:180\u20133.","journal-title":"Haematologica"},{"key":"1031_CR43","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","volume":"4","author":"G Montalban-Bravo","year":"2020","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020;4:482\u201395.","journal-title":"Blood Adv"},{"key":"1031_CR44","doi-asserted-by":"publisher","first-page":"106402","DOI":"10.1016\/j.leukres.2020.106402","volume":"95","author":"A Britt","year":"2020","unstructured":"Britt A, Mohyuddin GR, McClune B, Singh A, Lin T, Ganguly S, et al. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leuk Res. 2020;95:106402.","journal-title":"Leuk Res"},{"key":"1031_CR45","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536\u201347.","journal-title":"N Engl J Med"},{"key":"1031_CR46","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","volume":"38","author":"C Bally","year":"2014","unstructured":"Bally C, Ad\u00e8s L, Renneville A, Sebert M, Eclache V, Preudhomme C, et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res. 2014;38:751\u20135.","journal-title":"Leuk Res"},{"key":"1031_CR47","doi-asserted-by":"crossref","unstructured":"Komrokji RS. Myelodysplastic neoplasms (MDS) classification from WHO 2017 to WHO 2022 and ICC 2022: an expanded analysis of 7017 patients on behalf of the International Consortium for MDS (ICMDS). 2023 European Hematogloy Association Hybrid Congress; 10 June; Frankfurt, Germany (2023).","DOI":"10.1097\/01.HS9.0000967592.61626.0d"},{"key":"1031_CR48","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1182\/blood-2022-170158","volume":"140","author":"S Ball","year":"2022","unstructured":"Ball S, Singh AM, Ali NA, Aguirre LE, Jain AG, Schwabkey ZI, et al. A product of \u201cClash of Titans\u201d or true reflection of disease biology? Validation of 2022 WHO and ICC classifications in a large dataset of patients with myelodysplastic syndrome. Blood. 2022;140:1118\u201320.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01031-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01031-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01031-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:02:20Z","timestamp":1781820140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01031-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01031-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3795533\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"assertion":[{"value":"23 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}